WPSS.bio is a venture capital firm that invests in revolutionary diagnostics and treatments for central nervous system health.

WPSS.bio

Principia is an Italian Venture Capital firm with over Eur 80M under management. Currently Principia has two funds investing in digital start ups and expansion capital opportunities and in particular cases, we invest also in seed opportunities.

Principia SGR

McQuade Center for Strategic Research and Development invests in novel treatments for better health. Their aim is to seek out, identify, and fund creative early stages of research and development programs that have the potential to establish Otsuka's future product portfolio.

McQuade Center for Strategic Research and Development

Camden Partners provides growth capital to lower-middle market companies in the education, healthcare and technology-enabled business services sectors. In areas where there is little common knowledge, they make it their business to know intimately the companies and the money managers in which they invest. While many other investment management firms seek to excel as stock-pickers, they pursue opportunities where their experience and influence will make a positive difference to both their investors and the companies in which they invest.

Camden Partners

Perceptive Advisors is a privately owned hedge fund sponsor. The firm invests in the public equity markets across the globe. It employs a long/short equity strategy as a hedging technique while investing. The firm typically invests in the biotechnology and life sciences sectors to make its investments. Perceptive Advisors is based in New York, New York.

Perceptive Advisors

Founders Fund is a venture capital firm that invests at every stage in companies building revolutionary technologies. It has been investors, founders, and early employees of prominent technology companies. It has historically invested in a wide variety of sectors, including aerospace, artificial intelligence, advanced computing, energy, health, and consumer Internet.

Founders Fund

ATAI is a global biotech company builder that leverages a decentralized, technology- and data-driven platform model to serve millions of people suffering from mental health disorders. The company is committed to acquiring and efficiently developing innovative treatments that address significant unmet medical needs and lead to paradigm shifts in the mental health space. ATAI Life Sciences was founded in 2018 and is based in Munich, Bayern, Germany.

ATAI Life Sciences

They aim to support and nourish passionate entrepreneurs and inspiring brands that will make the daily lives of people healthier, happier, and more enlightened. They’re guided by their own experiences as entrepreneurs, and  they view all of their investments as partnerships—working with the founders to reach their unique goals. As individual investors, they are open to different paths to growth and exit strategies, and this flexibility is central to the promise they make their brands: they’re here to help you win big.

Able Partners

Presight Capital is a venture capital firm investing in the most ambitious founders across sectors, stages, and geographies.  Presight takes a global approach to early-stage investment opportunities in software, frontier technologies & biotech, backed by Apeiron, the family office of Christian Angermayer, and a group of world-class investors: Moore Capital, Point72, Mike Novogratz (former CIO of Fortress Investment Group), Martin Chavez (former CFO of Goldman Sachs), Alan Howard (Brevan Howard), Brent Hoberman (Founders Forum), and many successful entrepreneurs and investors who contribute their respective network and experience.

Presight Capital

Skyviews Life Science is a privately held advisory company specializing in personalized health. Skyviews Life Science identifies investment opportunities in companies at the growing interface between biotechnology, advanced nutrition, and digital health. Skyviews Life Science focuses in private and public companies with better drugs, advanced technology platforms, preventive strategies, personalized solutions, and more natural foods that will improve people’s quality of life.

Skyviews Life Science

Soleus Capital

Noetic Fund is a venture fund launched by Grey House Partners GP Inc. to invest in emerging and early-stage wellness, therapeutic and pharmaceutical companies around the globe. The company has proudly taken the North Star pledge and believes in the importance of stewarding this sector in the right way. It aims to nurture the scientific advancement of mental, emotional, psychological and physical health by investing in alternative therapies, modalities, and sciences that are committed to optimizing our human experience.

Noetic Fund

COMPASS Pathways

Compass Pathways is a mental health care company that focuses on developing therapies for treatment-resistant depression. The company is involved in researching and developing psilocybin therapy, a psychedelic compound found in certain mushrooms, as a potential treatment for depression. Compass Pathways conducts clinical trials and research to assess the safety and efficacy of psilocybin-assisted therapy in patients who have not responded to conventional depression treatments. The company's goal is to bring evidence-based innovation to mental health care and address the significant unmet need for effective and accessible treatments for depression.

<div>Compass Pathways is a psychedelic biotechnology company founded in 2016 that researches the psychedelic compound psilocybin for treatment-resistant depression.</div>

Promising research and receding stigma are giving investors cannabis-boom flashbacks.

Psychedelic Medicine

Compass Pathways

COMPASS Pathways stock falls on Q3 update (CMPS:NASDAQ)

Mindful Health Solutions

To explore a scalable delivery model for COMP360 psilocybin treatment for treatment-resistant depression, currently under FDA review. The partnership will involve both parties sharing information on the delivery model of the COMP360 program.

Companies conducting research on psychedelic compounds and developing novel therapeutics.

Rapid Addition

To explore a scalable delivery model for COMP360 psilocybin treatment for treatment-resistant depression, currently under FDA review. The partnership will involve both parties sharing information on the delivery model of the COMP360 program. 

<div>
 
 Compass Pathways is a psychedelic biotechnology company founded in 2016 that researches the psychedelic compound psilocybin for treatment-resistant depression.
 
 
 The company&rsquo;s proprietary formulation of synthetic psilocybin, COMP360, received Breakthrough Therapy status from the US Food and Drug Administration (FDA) in 2018. It has completed
 <a href="https://sp-edge.com/updates/14283">
 
 Phase 2
 </a>
 
 trials and plans to conduct Phase 3 trials in December 2022. It also claims to have conducted the world's largest psilocybin therapy trial with 216 patients.&nbsp;
 
 
 It has been granted 10 patents as of September 2022, with several others pending. The company has offices in London and New York. In September 2020, Compass Pathways became the first psychedelic company to be listed on the NASDAQ exchange and raised USD 144 million via a public offering afterward, in April 2021. For
 <a href="https://sp-edge.com/updates/16800">
 
 FY2022
 </a>
 
 net losses widened by 27.6% YoY to USD 91.5 million.&nbsp;
 
 
 Key customers and partnerships&nbsp;
 
 
 The company has partnerships with various institutions, including The Aquilino Cancer Center, Depression, and Bipolar Support Alliance, The Grady Trauma Project, and the National Council of Behavioural Health.&nbsp;
 
 
 Further, the company entered several partnerships in support of its product development initiatives, including 1) Mindful Health Solutions, to research on scalable psilocybin treatment model ( 
 <a href="https://sp-edge.com/updates/29087">
 May 2024
 </a>
 ), 2) Journey Clinical, to develop a deployment and training model for COMP360 ( 
 <a href="https://sp-edge.com/updates/28939">
 April 2024 
 </a>
 ), 3) Hackensack Meridian Health, to support research efforts using psilocybin in mental health treatments ( 
 <a href="https://sp-edge.com/updates/25618">
 January 2024 
 </a>
 ), and 4) Greenbrook TMS, to explore delivery models for COMP360 ( 
 <a href="https://sp-edge.com/updates/25237">
 January 2024 
 </a>
 ).
 
</div>

<div>
 
 Canadian biotech firm Core One Labs maintains three primary business operations: 1) developing novel delivery systems for psychedelic medicines, 2) psilocybin manufacturing, and 3) medical clinics to provide psychedelic-assisted psychotherapy. The company has developed proprietary technology with infused strips that dissolve immediately when placed in the patient&rsquo;s mouth to deliver molecules with a higher level of bioavailability. The company plans to advance this technology to incorporate psychedelic molecules, particularly psilocybin.&nbsp;
 
 
 Core One Labs also claims it has discovered a patentable method of producing high-quality psilocybin, which it may license to pharmaceutical companies. Additionally, the company has two psychedelic clinics in Vancouver that currently support clinical trials and maintain a database of more than 275,000 patients. The company acquired Vocan Biotechnologies and Akome Biotech in May 2021 for undisclosed amounts. Akome is developing a patent-pending psychedelic drug formulation for the treatment of Alzheimer&rsquo;s Disease.&nbsp;
 
 
 Core One Labs is listed on the Canadian Securities Exchange (CSE) and OTC markets.
 
 
</div>

Core One Labs

<div>
 
 Vancouver-based Lobe Sciences (formerly GreenStar Biosciences) is a biotechnology company developing psychedelic medicines (microdose applications) and medical devices for efficient drug delivery. The company&rsquo;s main focus is the treatment of mild traumatic brain injury and post-traumatic stress disorder (PTSD). It is also conducting early studies on psilocybin combined with N-acetylcysteine (NAC), and MDMA combined with NAC as a treatment. Lobe is also developing a patent pending nasal mist transducer device for the delivery of medicines directly to the brain&rsquo;s olfactory bulb.&nbsp;
 
 
 In June 2020, Lobe acquired Eleusian Biosciences, a company focused on the development of psychedelic medicine which expanded its intellectual property portfolio with three US patent applications for psychedelic therapeutics. Lobe is also collaborating with the University of Miami&rsquo;s Miller School of Medicine to conduct preclinical studies. After its restructuring and name change, the company started trading on the Canadian Securities Exchange (CSE) in November 2020.
 
 
 
</div>

Lobe Sciences

<div>
 
 Cybin is a psychedelic biotechnology company developing treatments for psychiatric and neurological conditions. Through its Serenity Life Science division, Cybin conducted Phase II of clinical trials on using psilocybin to treat major depressive disorder. Additionally, the company's Nature's Journey division focuses on creating non-psychedelic medicinal and nutraceutical mental health products.
 
 
 Cybin is actively building a patent portfolio, including chemically-synthesized compounds, delivery mechanisms, protocols, and new drug formulations. It has also filed an International Patent Application through the Patent Cooperation Treaty, potentially covering 153 countries.&nbsp;
 
 
 In July 2023, the company announced 
 <a href="https://sp-edge.com/updates/20076">
 EMBARKCT, 
 </a>
 a streamlined version of its EMBARK training program for pivotal studies of lead candidates, CYB003 for major depressive disorder and CYB004 for generalized anxiety disorder, respectively. In 
 <a href="https://sp-edge.com/updates/27577">
 March 2024
 </a>
 , the company received a breakthrough designation from the FDA for CYB003, and expects to initiate Phase III clinical trials for the program by mid-2024.
 
 
 Cybin implements an M&amp;A strategy to grow in the psychedelic industry. It did a reverse takeover of Charmin in June 2020, raising CAD 45 million (USD 35.5 million) for clinical studies. It acquired Adelia Therapeutics in December 2020, adding novel treatments and patent applications. Also in 
 <a href="https://sp-edge.com/updates/21335">
 August 2023 
 </a>
 it acquired 
 <a href="https://sp-edge.com/companies/470858">
 Small Pharma 
 </a>
 in an all-share transaction to strengthen its psychedelic portfolio.&nbsp;
 
 
 Founded in 2019, Cybin is listed on the NEO exchange under the ticker symbol &ldquo;CYBN&rdquo; and was uplisted to the NYSE American Stock Exchange in July 2021 under the same symbol. For FY2023, the company reported a decrease in net loss by 29.7% YoY to CAD 47.5 million (USD 35 million).&nbsp;
 Further in 
 <a href="https://sp-edge.com/updates/33849">
 September 2024
 </a>
 , it completed a 38-to-1 share consolidation of its common stock which reduced the number of outstanding common shares to ~20 million. 
 
 
 Key customers and partnerships&nbsp;
 
 
 In July 2020, Cybin expanded its operations and research activities in the European region via research partnerships and transferred its intellectual property assets to its fully-owned Irish subsidiary (formed in May 2021). In July 2023, the company partnered with 
 <a href="https://sp-edge.com/updates/20455">
 Worldwide Clinical Trials
 </a>
 to develop new psychedelic-based treatment options for mental health conditions, including major depressive disorder. Further, in September 2023, the company partnered with 
 <a href="https://sp-edge.com/updates/22180">
 Fluence
 </a>
 to support Cybin's EMBARK facilitator training program.
 
</div>

Cybin

<div>
 
 Canadian cannabinoid-based therapeutics company BioNxt Solutions
 (formerly Xphyto Therapeutics) announced in November 2020 that it has expanded its drug development program to incorporate a number of psychedelic compounds. This includes substances such as psilocybin, mescaline, LSD, MDMA, and DMT. Xphyto&rsquo;s initial focus is on developing standardized drug formulations with efficient delivery mechanisms for therapeutic use.
 
</div>

BioNxt Solutions

<div>
 
 New York-based Gilgamesh Pharmaceuticals is a biotechnology company developing psychedelic-inspired medicines for neuropsychiatric conditions such as depression, anxiety, addiction, and cognitive deficits. The company has three research programs in its pipeline: 1) Serotonergic Micro-Dose&ndash;a non psychedelic therapeutic treatment for attention deficit hyperactivity disorder (ADHD) and mood/anxiety disorders, 2) Arylcyclohexylamine&ndash;an improved molecule of ketamine for treatment-resistant depression and opiate use disorder, and 3) Novel Ibogaine Analogue&ndash;for the treatment of substance use disorders.&nbsp;
 
 
 Gilgamesh is one of the few psychedelic companies launched by the startup accelerator Y Combinator, and as such enjoys the accelerator&rsquo;s world-famous business expertise and network.
 
 
 Key customers and partnerships
 
 
 In 
 <a href="https://sp-edge.com/updates/29382">
 May 2024
 </a>
 , the company partnered with AbbVie to leverage AbbVie's psychiatric expertise and Gilgamesh's research platform to create novel &quot;neuroplastogens.&quot; 
 
 
 Funding and Financials
 
 
 In 
 <a href="https://sp-edge.com/updates/27575">
 March 2024
 </a>
 , the company received a grant of&nbsp; USD 14 million from the National Institute on Drug Abuse to develop the GM-3009 compound. Prior to this, it raised USD 39 million in a 
 <a href="https://sp-edge.com/updates/15359">
 Series B 
 </a>
 funding round led by Prime Movers Lab in December 2022. 
 
</div>

Gilgamesh Pharmaceuticals

Companies operating digital platforms to deliver psychedelic therapies including psychedelic integration, virtual experiences, and mental coaching and tracking. AI drug discovery companies specializing in psychedelic therapeutics are also included.

Companies operating clinics and treatment centers to deliver psychedelic therapies.

Companies supplying psychedelic compounds through cultivation, chemical synthesis and biosynthesis for medical research and drug development.

Companies building a patent portfolio of novel analogs and derivatives of first-generation psychedelics and new drug delivery mechanisms. 

ANALYST_QUICK_TAKE

<div>

 UK-based psychedelic company, Compass Pathways, is making major changes, laying off 30% of its workforce. This decision is driven by the company's intent to concentrate on its principal project: the development of COMP360, a psilocybin-based therapy aimed at treatment-resistant depression (TRD). 
 
 In order to effectively allocate its resources towards the COMP360 project, Compass Pathways is putting a temporary hold on all other pipeline projects. The company has also revised its data readout schedules for ongoing Phase III trials. The updated timeline suggests that trial COMP005's data will be available in the second quarter of 2025, and trial COMP006's results will be released in the latter half of 2026. The need for these delays stem from the logistical issues encountered in managing patient flow, scheduling, and initiating test sites in Europe. 
 
</div> Analyst QuickTake: 
 This move follows the recent FDA <a href="https: 
//sp-edge.com/updates/32520"> rejection </a> of Lykos Therapeutics' application for MDMA-assisted therapy for PTSD in August 2024, which led Lykos to <a href="https: 
//sp-edge.com/updates/32707"> lay off </a> around 75% of its workforce. Compass appears to be taking a similar approach, aiming to stabilize resources to support an eventual approval application.

Compass Pathways

EDGE Insights

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless